紫杉醇联合草酸铂或顺铂治疗晚期非小细胞肺癌48例被引量：5

A Comparison Between Paclitaxel Plus Oxaliplatin and Paclitaxel plus Cisplatin for Treatment of 48 Cases with Advanced Non-Small Cell Lung Cancer

下载PDF

导出

摘要 [目的]比较紫杉醇加草酸铂与紫杉醇加顺铂治疗晚期非小细胞肺癌的疗效和毒副反应。[方法]48例晚期非小细胞肺癌(NSCLC)患者随机分为紫杉醇加草酸铂组(TO)组(24例)和紫杉醇加顺铂组(TP)组(24例)。TO组:紫杉醇135mg/m2静滴,d1,草酸铂130mg/m2静滴,d1;TP方案:顺铂30mg/m2静滴,d1～3,紫杉醇用法同TP方法。每例均完成2个周期化疗后评价疗效及毒副反应。[结果]TO组和TP组有效率分别为37.5%和41.6%(P>0.05);TO组中位缓解期、中位生存期分别为20周和37周;TP组分别为18周和35周(P>0.05)。TO组与TP组白细胞减少发生率分别为42.85%和83.33%(P<0.05);恶心呕吐发生率分别为16.67%和45.83%(P<0.05);周围神经毒性发生率分别为37.5%和12.5%(P<0.05)。[结论]TO方案与TP方案治疗晚期NSCLC疗效相当,TO方案消化道不良反应轻,可作为治疗晚期NSCLC的一线或二线方案。

作者谢国明郭建新

机构地区宁波市鄞州人民医院

出处《中国肿瘤》 CAS 2006年第5期333-334,共2页 China Cancer

关键词肺肿瘤紫杉醇草酸铂顺铂药物疗法

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1廖开莲,肖华伍,罗永忠,欧阳周,席许平.紫杉醇联合顺铂治疗28例晚期非小细胞肺癌临床观察[J].癌症,2001,20(8):882-882. 被引量：20
2Klastersky J,Scnlier JP.Dose-finding study of paclitaxel plus cisplatin in patients with non-small cell lung cancer[J].Lung Cancer,1995,12(1):117-125.
3Doroshow JH,Synold TW,Gandara D,et al.Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfcnction a preliminary report of the National Cancer Institute Organ Dysfunction Working Group[J].Semin Oncol,2003,3014 (Suppl 152):14-19.
4Rixe O,Ortuzar W,Alvarez M,et al.Oxaliplatin,tetreplatin,cisplatin,and carboplatin.Sepectrum of activity in drug resistant cell lines of the national cancer institutes anticancer drug screen panal[J].Biochem Pharmacol,1996,52(12):1855-1859.
5Monnet H,De CH,Soulie P,et al.Oxaliplatin plus vionorelbine in advanced non-small cell lung cancer:final results of a muhicenter phase Ⅱ stundy[J].Ann Oncol,2002,13(1):103-107.
6Winegarden TD,Mauer AM,Otterson GA,et al.A phase Ⅱ study of oxaliplatin and paclitaxel with advanced nonsmall cell lung cancer[J].Ann Oncol,2004,15(6):915-920.
7谢聪颖,吴式,张萍.紫杉醇联合草酸铂治疗复治晚期非小细胞肺癌的疗效[J].癌症,2004,23(8):947-950. 被引量：16

二级参考文献13

1孙燕.临床肿瘤内科手册，第3版[M].北京:人民卫生出版社,1996.353-355.
2孙燕，临床肿瘤内科手册（第3版），1996年，379页
3Raymond E,Chaney SG,Taamma A,et al. Oxaliplatin: a review of preclinical and clinical studies [J]. Ann Oncol,1998,9(10):1053- 1071.
4Rixe O,Ortuzar W,Alvarez M,et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel [J]. Biochem Pharmacol,1996,52(12):1855- 1859.
5Monnet I,Brienza S,Hugret F,et al. Phase Ⅱ study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). AT-TIT. Association pour le Traitement des Tumeurs Intra Thoraciques [J]. Eur J Cancer,1998, 34(7):1124- 1127.
6Faivre S,Kalla S,Cvitkovic E,et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma:an investigator-originated compassionate-use experience [J]. Ann Oncol,1999, 10(9):1125- 1128.
7Jamieson SM,Liu J,Hsu T,et al. Paclitaxel induces nuckeolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity [J]. Br J Cancer,2003, 88(12):1942- 1947.
8Liu J,Kraut EH,Balcerzak S,et al. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat [J]. Cancer Chemother Pharmacol,2002, 50(6):445- 453.
9陈丽荣,郑树,MCWilingham,范伟民.紫杉醇诱发人乳癌细胞凋亡的机制研究[J].中华肿瘤杂志,1997,19(2):103-106. 被引量：82
10吴海鹰,管忠震,林桐榆,蔡树模,许立功,黄荣丽,黄惠芳,李龙芸,鲍云华,江泽飞.国产紫杉醇治疗恶性肿瘤的Ⅱ期临床研究[J].中华肿瘤杂志,1998,20(2):148-152. 被引量：95